Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients.
Antibiotic-resistant coagulase-negative staphylococci are a frequent cause of infection in indwelling central venous (Hickman) catheters. Teicoplanin has been evaluated in the treatment of 19 immunosuppressed patients with staphylococcal Hickman catheter infections, nine of whom were septicaemic. All infections were eradicated, with minimal side effects. In 16 cases, the catheter was retained until no longer required. Two recurrent infections were eradicated by a second course of teicoplanin. We conclude that teicoplanin is an effective and well-tolerated antibiotic in the treatment of Hickman catheter infections in immunosuppressed patients.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D009369:Neoplasms / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology; D017334:Teicoplanin
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin